Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Lintuzumab-Ac225 Exerts Mutation Agnostic Antileukemic Activity in Preclinical Models of AML

Amanda Chin, Rubin Jiao, Kevin J.H. Allen, Jason Li, Mary Chen, Madhuri Vusirikala, Avinash Desai, Le-Cun Xu, Patrik Brodin, Monideepa Roy, Mackenzie Malo, Denis Beckford-Vera, Ekaterina Dadachova, Helen Kotanides

Blood (2024) 144 (Supplement 1): 5801.

https://doi.org/10.1182/blood-2024-204282

Published: 2024

Journal Articles

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash Desai, Mary Chen, Patrik Brodin, Kate L Li, Mojisola Rotibi, Umar Sayeed, Alexandra M. Harrington, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2024-201559

Published: 2024

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

Gail J. Roboz, Laura E. Finn, Johnnie J. Orozco, Mohamed Hegazi, Avinash Desai, Mary Chen, Gary J. Schiller

Blood (2023) 142 (Supplement 1): 1539.

https://doi.org/10.1182/blood-2023-178802

Published: 2023

Journal Articles

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

Gary J. Schiller, Laura Finn, Mohamed M. Hegazi, Johnnie J. Orozco, Avinash Desai, Mary M Chen, Gail J. Roboz

Blood (2022) 140 (Supplement 1): 3336–3337.

https://doi.org/10.1182/blood-2022-157588

Published: 2022

Journal Articles

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Mark B. Geyer, Briana Cadzin, Kinga Hosszu, Brigitte Senechal, Jennifer A. Spross, Alexis Mark, Avinash Desai, Elizabeth R. Cathcart, M. Lia Palomba, Neeta Pandit-Taskar

Blood (2022) 140 (Supplement 1): 10341–10342.

https://doi.org/10.1182/blood-2022-167962

Published: 2022

Journal Articles

Patient-Relevant Experiences and Impacts of Acute Myeloid Leukemia: Evidence from Online Social Networks-Based Qualitative Research

Shruti Kusumgar, MBA, Kevin Johnson, Monica Belford, Avinash Desai, MD, Jianming He, PhD

Blood (2015) 126 (23): 4523.

https://doi.org/10.1182/blood.V126.23.4523.4523

Published: 2015

Journal Articles

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Blood (2013) 122 (21): 3187.

https://doi.org/10.1182/blood.V122.21.3187.3187

Published: 2013

Journal Articles

Use of a Claims Database to Characterize and Estimate the Incidence of Castleman's Disease

Maneesha Mehra, M.SC, MPH, Nicole Cossrow, MPH, PhD, Robert A Stellhorn, MS, Jessica Vermeulen, MD, PhD, Avinash Desai, MD, Nikhil C. Munshi, MD

Blood (2012) 120 (21): 4253.

https://doi.org/10.1182/blood.V120.21.4253.4253

Published: 2012

Journal Articles

Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,

Dina Gifkins, PhD, Megan McAuliffe, ScD, Amy Matcho, BS, Jane Porter, MS, Scott Chavers, PhD, Maria Ponsillo, MD, Jay King, MD, Avinash Desai, MD, Andrew Cakana, MD, Dixie-Lee Esseltine, MD

Blood (2011) 118 (21): 3972.

https://doi.org/10.1182/blood.V118.21.3972.3972

Published: 2011

Journal Articles

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Jesús F San Miguel, MD PhD, Paul G. Richardson, MD, Robert Z. Orlowski, MD, PhD, Hartmut Goldschmidt, Deyanira Corzo, MD, Carol Satler, Dixie-Lee Esseltine, MD, FRCPC, Rachel Neuwirth, MS, Maria Ponsillo, MD, Andrew Z Cakana, MD, FRCPath, Jay King, MD, William M Deraedt, PhD, Avinash Desai, Yana Lutska, Dina Gifkins, PhD, Kevin Liu, PhD, Pieter Sonneveld, MD, PhD

Blood (2011) 118 (21): 2933.

https://doi.org/10.1182/blood.V118.21.2933.2933

Published: 2011

NARROW

Lintuzumab-Ac225 Exerts Mutation Agnostic Antileukemic Activity in Preclinical Models of AML

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Updated Results from Phase 1 Study of Targeted Radiotherapy with Lintuzumab-Ac225 in Combination with Venetoclax in Relapsed/Refractory AML

Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory AML

An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Patient-Relevant Experiences and Impacts of Acute Myeloid Leukemia: Evidence from Online Social Networks-Based Qualitative Research

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

Use of a Claims Database to Characterize and Estimate the Incidence of Castleman's Disease

Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database,

Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only